Literature DB >> 31050101

Clinical analysis of Chinese anti-low-density-lipoprotein-receptor-associated protein 4 antibodies in patients with myasthenia gravis.

M Li1, J Han2, Y Zhang3, J Lv2, J Zhang2, X Zhao2, L Ren1, H Fang2, J Yang3, Y Zhang3, X Cui4, Q Zhang4, Q Li5, Y Du5, F Gao2.   

Abstract

BACKGROUND AND
PURPOSE: Low-density-lipoprotein-receptor-associated protein 4 (LRP4) autoantibodies have recently been detected in myasthenia gravis (MG), but little is known about the clinical characteristics associated with this serological type. In this study, the clinical features of Chinese patients with anti-LRP4 antibody-positive MG were characterized.
METHODS: A total of 2172 MG serum samples were collected from patients in various parts of China. An enzyme-linked immunosorbent assay was used to detect acetylcholine receptor (AChR) antibody and titin antibody, and cell-based assays were used to detect muscle-specific kinase antibody and LRP4 antibody. Clinical data for patients with MG were collected from different provinces in China.
RESULTS: In total, 16 (0.8%) patients with LRP4-MG were found amongst 2172 total patients, including three patients with AChR/LRP4-MG. Additionally, 13 (2.9%) patients with LRP4-MG were found amongst 455 patients with double seronegative MG. The ratio of males to females for these 13 patients was 1:1.6, and 53.8% patients were children. A total of 91.7% of cases exhibited initial ocular involvement, and 58.3% of cases exhibited simple eye muscle involvement. Responses to acetylcholinesterase inhibitors and prednisone were observed.
CONCLUSION: The expanded sample confirmed that the positive rate of LRP4 antibodies in China is lower than that in western countries. Our results highlighted the differences between LRP4-MG and other antibody groups. Children and female patients with LRP4-MG have a higher prevalence, often involving the ocular muscles and limb muscles. The clinical symptoms are mild, and satisfactory responses to treatment are often achieved.
© 2019 EAN.

Entities:  

Keywords:  autoantibody; double seronegative (dSN); low-density-lipoprotein-receptor-associated protein 4 (LRP4); myasthenia gravis (MG); triple seronegative (TSN)

Mesh:

Substances:

Year:  2019        PMID: 31050101     DOI: 10.1111/ene.13979

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  6 in total

Review 1.  Myasthenia Gravis: Autoantibody Specificities and Their Role in MG Management.

Authors:  Konstantinos Lazaridis; Socrates J Tzartos
Journal:  Front Neurol       Date:  2020-11-30       Impact factor: 4.003

Review 2.  Controversies in Ocular Myasthenia Gravis.

Authors:  Amelia Evoli; Raffaele Iorio
Journal:  Front Neurol       Date:  2020-11-30       Impact factor: 4.003

Review 3.  Bedside and laboratory diagnostic testing in myasthenia.

Authors:  Katie Yoganathan; Alexander Stevenson; Awais Tahir; Ross Sadler; Aleksandar Radunovic; Naveed Malek
Journal:  J Neurol       Date:  2022-02-10       Impact factor: 6.682

Review 4.  Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics.

Authors:  Konstantinos Lazaridis; Socrates J Tzartos
Journal:  Front Immunol       Date:  2020-02-14       Impact factor: 7.561

5.  A Patient with Fulminant Myasthenia Gravis Is Seropositive for Both AChR and LRP4 Antibodies, Complicated by Autoimmune Polyglandular Syndrome Type 3.

Authors:  Hiroyasu Inoue; Kentaro Yamada; Asami Fujii; Tatsuya Tomonari; Kotaro Mizuno; Keiko Mita; Osamu Higuchi; Masaya Akao; Noriyuki Matsukawa
Journal:  Intern Med       Date:  2020-05-26       Impact factor: 1.271

6.  Antibodies to Full-Length Agrin Protein in Chinese Patients With Myasthenia Gravis.

Authors:  Shumin Wang; Haonan Yang; Rongjing Guo; Lulu Wang; Yingna Zhang; Jie Lv; Xue Zhao; Jing Zhang; Hua Fang; Qingyong Zhang; Yunke Zhang; Junhong Yang; Xinzheng Cui; Peiyang Gao; Ting Chang; Feng Gao
Journal:  Front Immunol       Date:  2021-12-08       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.